{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-217037","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2026-05-11T20:58:18+00:00","discovered_at":"2026-05-11T20:59:00.309410+00:00","generated_at":"2026-05-11T21:01:58.248662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Biomea Fusion Q1 net loss $12.4M; cash $45.1M; icovamenib Phase II T2D data due Q4 2026","bullets":["Net loss $12.4M ($1.6M SBC) vs $29.3M in Q1 2025; cash, equivalents & restricted cash $45.1M at Mar 31, 2026; runway into Q1 2027.","R&D expenses $9.1M (down from $22.9M YoY); G&A $3.7M (down from $6.8M).","Icovamenib chronic tox studies completed; Phase II T2D trials COVALENT-211/-212 dosing; topline 26-week data expected Q4 2026.","Phase II T1D COVALENT-112: 52% C-peptide AUC increase at week 12 (200mg); preservation through week 52; plan for investigator-sponsored trial.","Phase I GLP-1 obesity trial (BMF-650, GLP-131) ongoing; initial 28-day weight data expected Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-217037","json":"https://secwatch.observer/filing/0001193125-26-217037.json","markdown":"https://secwatch.observer/filing/0001193125-26-217037.md","text":"https://secwatch.observer/filing/0001193125-26-217037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526217037/0001193125-26-217037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526217037/bmea-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T21:01:58.248662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac0b56463301debcd48abee2fe7e78187d487a93","claim":"Biomea Fusion, Inc. reported first quarter ended March 31, 2026 results: net income net loss of $12.4 million.","evidence_excerpt":"Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526217037/0001193125-26-217037-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"net loss of $12.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}